Yantai Dongcheng Biochemicals announced that its holding subsidiary Lanna Cheng has received the clinical trial approval notice for 18F-LNC1007 injection issued by the National Medical Products Administration. This drug is a new dual-targeting radioactive internal diagnostic drug intended for the diagnosis of FAP and αvβ3 positive adult solid tumors.
东诚药业：控股子公司蓝纳成获得18F-LNC1007注射液临床试验批准
Yantai Dongcheng Biochemicals: The holding subsidiary Lanna Cheng has obtained the clinical trial approval for 18F-LNC1007 injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated